42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)

Dafna D Gladman

doi:10.1016/j.jaad.2023.07.759

42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)

Dafna D Gladman

https://doi.org/10.1016/j.jaad.2023.07.759

Copy DOI

Journal: Journal of the American Academy of Dermatology

Publication Date: Sep 1, 2023

#Guselkumab #Psoriatic Arthritis + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)

Full Text